PATENT CLAIM ANALYSIS

Application Number: 15894741
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-12
Patent Classification: ["424", "158100"]

Abstract:
Therapeutic antibodies having binding specificity for ROR-1 expressed on cancer cells (particularly leukemic and lymphomic cells) and pharmaceutical compositions containing one or more such antibodies for use in treating cancer. Methods for diagnosing such cancers through in vitro detection of binding to ROR-1 protein expressed on putative cancer cells are also provided.

Claim (Index 39):
The method according to  claim 38 , wherein said cancer is selected from the group consisting of lymphoma, CLL, small lymphocytic lymphoma, marginal cell B-Cell lymphoma, Burkett's Lymphoma, renal cell carcinoma, colon cancer, colorectal cancer, breast cancer, epithelial squamous cell cancer, melanoma, myeloma, stomach cancer, brain cancer, lung cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, prostate cancer, testicular cancer, thyroid cancer, and head and neck cancer.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 88.0
- Lexical Diversity: 1.36585
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13997934', '14846400', '15346967', '15619119', '14422519']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8584808667260221
- 35 USC 102 Novelty (BERT): 0.5754685498849498
- Combined Prediction Score: 0.8301796350419148
- Mean Citation Score: 532.8721939999998
- Max Citation Score: 580.2986
- Similarity Product: 370.8586750426888

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test